Edward Nash
Stock Analyst at Canaccord Genuity
(4.06)
# 471
Out of 5,090 analysts
83
Total ratings
52%
Success rate
13.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $526 → $587 | $577.30 | +1.68% | 12 | Nov 13, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $106 → $107 | $38.55 | +177.56% | 2 | Nov 12, 2025 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $14 → $16 | $8.72 | +83.49% | 7 | Nov 7, 2025 | |
| AKRO Akero Therapeutics | Downgrades: Hold | $73 → $54 | $54.55 | -1.01% | 7 | Oct 9, 2025 | |
| SGMT Sagimet Biosciences | Maintains: Buy | $28 | $6.39 | +338.18% | 2 | Oct 2, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 | $4.13 | +384.26% | 3 | Sep 30, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $140 | $86.11 | +62.59% | 10 | Sep 25, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $62 | $29.45 | +110.53% | 3 | Sep 17, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $35.00 | +34.29% | 10 | Apr 10, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $1.59 | +466.04% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.21 | +230.58% | 2 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $76.75 | +15.96% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $1.05 | +661.90% | 3 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $10.42 | +63.15% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.69 | -25.65% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.12 | +15,971.43% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $36.38 | +125.40% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $4.26 | +1,777.93% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $21.33 | +125.04% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $4.88 | +13,233.33% | 1 | Nov 8, 2017 |
Madrigal Pharmaceuticals
Nov 13, 2025
Maintains: Buy
Price Target: $526 → $587
Current: $577.30
Upside: +1.68%
Viking Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $106 → $107
Current: $38.55
Upside: +177.56%
Ventyx Biosciences
Nov 7, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $8.72
Upside: +83.49%
Akero Therapeutics
Oct 9, 2025
Downgrades: Hold
Price Target: $73 → $54
Current: $54.55
Upside: -1.01%
Sagimet Biosciences
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $6.39
Upside: +338.18%
Inventiva
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $4.13
Upside: +384.26%
Corcept Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $140
Current: $86.11
Upside: +62.59%
Celldex Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $29.45
Upside: +110.53%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $35.00
Upside: +34.29%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $1.59
Upside: +466.04%
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.21
Upside: +230.58%
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $76.75
Upside: +15.96%
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.05
Upside: +661.90%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $10.42
Upside: +63.15%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.69
Upside: -25.65%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.12
Upside: +15,971.43%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $36.38
Upside: +125.40%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $4.26
Upside: +1,777.93%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $21.33
Upside: +125.04%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $4.88
Upside: +13,233.33%